Global Cord Blood Corporation (CO) Tops Q2 EPS by 1c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Global Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2020
November 26, 2019 4:16 PM ESTHONG KONG, Nov. 26, 2019 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the second quarter and first half of fiscal year 2020 ended September 30, 2019.
Second Quarter of Fiscal 2020 Highlights
Revenues increased by 26.9% year over year ("YoY") to RMB313.5 million ($43.9 million). New subscribers and accumulated subscriber base were 21,551 and 791,812[1], respectively. Gross profit increased by 32.7% YoY to RMB265.1 million ($37.1... More